Navigation Links
Christopher Brennan Joins PharmaNet Development Group as General Counsel
Date:9/22/2009

PRINCETON, N.J., Sept. 22 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Christopher S. Brennan has joined the Company as general counsel.

"We are very pleased to have Chris join the PharmaNet Development Group management team," commented Jeffrey P. McMullen, president and chief executive officer. "His diversified experience and expertise will bring valuable insight to the Company and support our growth strategies."

Previously, Mr. Brennan held the position of general counsel at a specialty pharmaceutical company and worked in private practice as a corporate transactional attorney at two prominent, multi-national law firms -- Cravath, Swaine & Moore LLP and Dechert LLP. While at these two global law firms, Mr. Brennan worked along side management teams from various Fortune 500 companies while helping them to successfully undertake and complete company "mission critical" transactions in the areas of mergers and acquisitions, corporate financing, joint ventures, licensing, corporate partnering, private financing and public securities -- all primarily in the pharmaceutical and emerging life science market place.

Mr. Brennan graduated from Fordham University School of Law with honors. For the five years prior to entering law school, he managed multi-million dollar, high-technology projects and led large project teams from various disciplines as a Captain in the United States Air Force.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    E-mail: ahess@pharmanet.com


'/>"/>
SOURCE PharmaNet Development Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
2. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
3. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
4. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
7. Christopher and Dana Reeve Foundation Response to FDA Clearance of Gerons Clinical Trial
8. VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer
9. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
10. DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice
11. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design team has ... team explored how bacterial properties can be applied to fabric and formed into living ... move in response to humidity change. The team harvested Natto cells and applied them ...
(Date:4/29/2016)... ... 2016 , ... Amendia, Inc., a leading designer, developer, manufacturer ... completion of a significant transaction and partnership that positions Amendia for accelerated growth ... Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm specializing in middle ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... to transform technology into a viable company, CereScan’s CEO, John Kelley, joined other ... a recognized leader and mentor in the Denver area business community, shared his ...
(Date:4/29/2016)... ... , ... Intelligent Implant Systems announced today that the two-level components for the ... United States. These components expand the capabilities of the system and allow Revolution™ ... October of 2015, the company has seen significant sales growth in 1Q 2016, and ...
Breaking Biology Technology:
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... http://www.apimages.com ) - --> - Renvoi : ... - --> --> ... solutions biométriques, fournit de nouveaux lecteurs d,empreintes digitales ... LF10 de DERMALOG sera utilisé pour produire des ...
(Date:3/9/2016)... YORK , March 9, 2016 This ... and future states of the RNA Sequencing (RNA Seq) ... segments such as instruments, tools and reagents, data analysis, ... Analyze various segments of the RNA-Sequencing market such as ... services Identify the main factors affecting each segment and ...
(Date:3/3/2016)... , March 3, 2016  2016FLEX, organized ... this week highlighting advancements in flexible, hybrid and ... record setting attendance - have gathered for short ... fast-growing field of electronics. The Flex Conference celebrates ... point for companies, R&D organizations, and universities contributing ...
Breaking Biology News(10 mins):